Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A retrospective analysis from The Australasian Bone Marrow Transplant Recipient Registry

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterised by significant constitutional symptoms due to raised inflammatory cytokine levels, reactive bone marrow fibrosis and extramedullary haematopoiesis, with risk of transformation to acute myeloid leukaemia. It is an uncommon disease which can be primary or secondary to other myeloproliferative neoplasms [1]. Disease severity is assessed by a number of prognostic scoring systems [2-5]. For instance, based on Dynamic International Prognostic Scoring System (DIPSS) Plus risk category, the estimated median survival of patients with MF ranges from 16 months to 15 years [3,5].

Source: Biology of Blood and Marrow Transplantation - August 25, 2020 Category: Hematology Authors: Y. Lwin, G. Kennedy, D. Gottlieb, J. Kwan, D. Ritchie, J. Szer, S. Milliken, P. Browett, A. Spencer, A. Butler, P. Bardy, M. Greenwood, T. Perera, S. He, A. McEwan, S. Larsen, H. Lai, D. Purtill, S. Tran, D. Aarons, N. Hamad Source Type: research